Sara Straniero

Dr. Sara Straniero


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
SSSara Straniero
Sara Straniero
ALAmit Laskar
Amit Laskar
CSChristina Savva
Christina Savva
JHJennifer H&Aumlrdfeldt
Jennifer H&Aumlrdfeldt
BABo Angelin
Bo Angelin
MRMats Rudling
Mats Rudling
Sara Straniero, Amit Laskar, Christina Savva, Jennifer Härdfeldt, Bo Angelin, Mats Rudling

1 January 2020 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
VVVeronika Voronova
Veronika Voronova
VSVictor Sokolov
Victor Sokolov
AAAmani Al-Khaifi
Amani Al-Khaifi
SSSara Straniero
Sara Straniero
CKChanchal Kumar
Chanchal Kumar
BABo Angelin
Bo Angelin
Disturbances of the enterohepatic circulation of bile acids (BAs) are seen in a number of clinically important conditions, including metabolic disorders, hepatic impairment, diarrhea, and gallstone disease. To facilitate the exploration of underlying pathogenic mechanisms, we developed a mathematical model built on quantitative physiological observations across different organs. The model consists of a set of kinetic equations describing the syntheses of cholic, chenodeoxycholic, and deoxycholic acids, as well as time-related changes of their respective free and conjugated forms in the systemic circulation, the hepatoportal region, and the gastrointestinal tract. The core structure of the model was adapted from previous modeling research and updated based on recent mechanistic insights, including farnesoid X receptor-mediated autoregulation of BA synthesis and selective transport mechanisms. The model was calibrated against existing data on BA distribution and feedback regulation. According to model-based predictions, changes in intestinal motility, BA absorption, and biotransformation rates affected BA composition and distribution differently, as follows: (1) inhibition of transintestinal BA flux (eg, in patients with BA malabsorption) or acceleration of intestinal motility, followed by farnesoid X receptor down-regulation, was associated with colonic BA accumulation; (2) in contrast, modulation of the colonic absorption process was predicted to not affect the BA pool significantly; and (3) activation of ileal deconjugation (eg, in patents with small intestinal bacterial overgrowth) was associated with an increase in the BA pool, owing to higher ileal permeability of unconjugated BA species. This model will be useful in further studying how BA enterohepatic circulation modulation may be exploited for therapeutic benefits.

1 April 2023 in Hepatology
Verified
Journal Article
Open access
FCFrancisco J. Caballero-Camino
Francisco J. Caballero-Camino
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
FWFredrik Wångsell
Fredrik Wångsell
AAAloña Agirre-Lizaso
Aloña Agirre-Lizaso
PRPaula Olaizola Rebe
Paula Olaizola Rebe
Jesús BañalesJesús Bañales
Jesús Bañales
Background and Aims: Cholestasis is characterized by intrahepatic accumulation of bile constituents, including bile acids (BAs), which promote liver damage. The apical sodium-dependent BA transporter (ASBT) plays an important role in BA reabsorption and signaling in ileum, bile ducts, and kidneys. Our aim was to investigate the pharmacokinetics and pharmacological activity of A3907, an oral and systemically available ASBT inhibitor in experimental mouse models of cholestasis. In addition, the tolerability, pharmacokinetics, and pharmacodynamics of A3907 were examined in healthy humans. Approach and Results: A3907 was a potent and selective ASBT inhibitor in vitro. In rodents, orally administered A3907 distributed to the ASBT-expressing organs, that is, ileum, liver, and kidneys, and dose dependently increased fecal BA excretion. A3907 improved biochemical, histological, and molecular markers of liver and bile duct injury in Mdr2 −/− mice and also had direct protective effects on rat cholangiocytes exposed to cytotoxic BA concentrations in vitro. In bile duct ligated mice, A3907 increased urinary BA elimination, reduced serum BA levels, and prevented body weight loss, while improving markers of liver injury. A3907 was well tolerated and demonstrated target engagement in healthy volunteers. Plasma exposure of A3907 in humans was within the range of systemic concentrations that achieved therapeutic efficacy in mouse. Conclusions: The systemic ASBT inhibitor A3907 improved experimental cholestatic disease by targeting ASBT function at the intestinal, liver, and kidney levels, resulting in marked clearance of circulating BAs and liver protection. A3907 is well tolerated in humans, supporting further clinical development for the treatment of cholestatic liver diseases.

1 March 2019 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
MRMats Rudling
Mats Rudling
ALAmit Laskar
Amit Laskar
SSSara Straniero
Sara Straniero
Mats Rudling, Amit Laskar, Sara Straniero

1 May 2016 in The Journal of nutrition, health and aging
Verified
Journal Article
Open access
PDF file
GCGabriella Cavallini
Gabriella Cavallini
SSSara Straniero
Sara Straniero
ADA. Donati
A. Donati
EBE. Bergamini
E. Bergamini
Objective There is substantial evidence that a diet rich in fruit and vegetables may reduce the risk of aging and stress oxidative associated diseases. It has been suggested that benefits associated with fruit and red wine consumption could be due to pooled antioxidant microcomponents in diet. The aim of this study was to investigate the antioxidant activities of pure resveratrol (a well known phytoalexin, RSV) and red wine polyphenols (RWP), using UV-B radiated isolated rat hepatocytes as a model of oxidative stress. Methods Rat hepatocytes were isolated by the collagenase method. The cells were loaded with resveratrol and/or polyphenols at different concentrations. The production of thiobarbituric acid reactive substances (TBARS) released by UV-B radiated cells and the levels of lipid-soluble antioxidants (Dolichol, Vitamin E, Coenzyme Q9 and Q10) were measured. Results Resveratrol had pro-oxidant or antioxidant effects depending on (lower or higher) dosage. RWP protection from photolipoperoxidation was dose-dependent and increased with dosage. Combination of the two compounds exhibited synergistic antioxidant effect, and made resveratrol effective both at lower and higher dosages. Conclusions These results suggest that resveratrol requires red wine polyphenols for optimum antioxidant activity.

1 August 2021 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
SSSara Straniero
Sara Straniero
ALA. Laskar
A. Laskar
CSC. Savva
C. Savva
JHJennifer Härdfeldt
Jennifer Härdfeldt
BAB. Angelin
B. Angelin
MRM. Rudling
M. Rudling